Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00754
UPID:
MA2B1_HUMAN
Alternative names:
Lysosomal acid alpha-mannosidase; Mannosidase alpha class 2B member 1; Mannosidase alpha-B
Alternative UPACC:
O00754; G5E928; O15330; Q16680; Q93094; Q9BW13
Background:
Lysosomal alpha-mannosidase, also known as Mannosidase alpha class 2B member 1, plays a crucial role in the catabolism of N-linked carbohydrates released during glycoprotein turnover. It is adept at cleaving all known types of alpha-mannosidic linkages, showcasing its vital function in cellular processes.
Therapeutic significance:
The protein is directly linked to Mannosidosis, alpha B, lysosomal, a lysosomal storage disease characterized by the accumulation of oligosaccharide chains. This condition manifests with a spectrum of symptoms, including intellectual disability and skeletal abnormalities, underscoring the protein's potential as a target for therapeutic intervention.